2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2021)

Lenvatinib plus pembrolizumab improves PFS, OS and ORR in advanced clear-cell RCC

Christina Lau, 20210315000000

Lenvatinib plus pembrolizumab significantly improves progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) vs sunitinib in treatment-naïve patients with advanced clear-cell renal cell carcinoma (RCC), results of the phase III CLEAR study have shown.

Apalutamide added on to abiraterone acetate, prednisone extends rPFS in mCRPC

Elaine Soliven, 20210312000000

Adding apalutamide (APA) to abiraterone acetate and prednisone (AAP) significantly extends radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with AAP only, according to the final analysis of the ACIS* trial presented at ASCO GU 2021.

Chemo continues to benefit UTUC patients, updated POUT analysis shows

Audrey Abella, 20210310100000

In an updated analysis of the phase III POUT* trial presented at ASCO GU 2021, peri-operative chemotherapy continued to improve disease-free survival (DFS) compared with surveillance in patients with upper tract urothelial cancer (UTUC).

Nivolumab + cabozantinib combo offers better QoL in advanced RCC

Elaine Soliven, 20210310000000

First-line treatment with nivolumab plus cabozantinib (NIVO+CABO) led to significantly better patient-reported quality of life (QoL) outcomes compared with sunitinib in patients with advanced renal cell carcinoma (RCC), according to an exploratory analysis of the CheckMate 9ER* trial presented at ASCO GU 2021.

Enfortumab vedotin improves survival in previously treated advanced urothelial carcinoma

Roshini Claire Anthony, 20210309180001

Enfortumab vedotin improved overall survival (OS) compared with chemotherapy in patients with previously treated, locally advanced or metastatic urothelial carcinoma (UC), according to interim results of the phase III EV-301 study.

SWOG 1500: PFS longer with cabozantinib than sunitinib in mPRCC

Elvira Manzano, 20210309113600

Cabozantinib reduces the risk of disease progression or death by 40 percent compared with the current standard sunitinib in patients with metastatic papillary renal cell carcinoma (mPRCC) – a primary malignant tumour of the renal tubular epithelium – in the phase 2 SWOG 1500 study.

N-803 shows promise for BCG-unresponsive NMIBC carcinoma in situ

Audrey Abella, 20210308135243

Intravesical administration of the IL-15RαFc* superagonist N-803 with BCG** demonstrated a strong efficacy and an excellent safety and tolerability profile in patients with BCG-unresponsive high-grade NMIBC*** carcinoma in situ, according to an interim analysis presented at ASCO GU 2021.

Lenvatinib + pembrolizumab shows CLEAR survival benefit over sunitinib in advanced RCC

Pearl Toh, 20210306140100

The combination therapy of lenvatinib plus pembrolizumab significantly improves survival outcomes compared with the standard-of-care treatment of sunitinib in the first-line setting for advanced renal cell carcinoma (RCC), according to the CLEAR* study presented at the 2021 ASCO GU Cancer Symposium.

Adjuvant nivolumab ups DFS in high-risk MIUC

CheckMate 274: Adjuvant nivolumab ups DFS in high-risk bladder cancer

Pearl Toh, 20210304150000

Treatment with the PD-1 immune checkpoint inhibitor nivolumab after radical surgery significantly extends disease-free survival (DFS) compared with placebo in patients with muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence, regardless of their PD-L1 status, according to the CheckMate 274 study presented at the 2021 ASCO GUCS.

Nivolumab+cabozantinib demonstrates durable efficacy for renal cancer

Audrey Abella, 20210304100000

In the extended follow-up of the phase III CheckMate 9ER trial, nivolumab + cabozantinib (NIVO+CABO) continued to fare better than sunitinib for the treatment of advanced renal cell carcinoma (aRCC), regardless of sarcomatoid (sRCC) status.